Synthesis and Characterization of High-Affinity 4, 4-Difluoro-4-bora-3a,4a-diaza-s-indacene-Labeled Fluorescent Ligands for Human β-Adrenoceptors

被引:42
作者
Baker, Jillian G. [1 ]
Adams, Luke A. [2 ]
Salchow, Karolina [1 ]
Mistry, Shailesh N. [2 ]
Middleton, Richard J. [2 ,3 ]
Hill, Stephen J. [1 ]
Kellam, Barrie [2 ]
机构
[1] Univ Nottingham, Sch Med, Inst Cell Signalling, Nottingham NG7 2UH, England
[2] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England
[3] CellAura Technol Ltd, Nottingham NG1 1GF, England
基金
英国生物技术与生命科学研究理事会;
关键词
PROTEIN-COUPLED RECEPTOR; NON-SPECIFIC BINDING; ADRENERGIC-RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CORRELATION SPECTROSCOPY; PROVIDE EVIDENCE; AGONIST ACTIONS; NERVOUS-SYSTEM; PHARMACOLOGY; LOCALIZATION;
D O I
10.1021/jm2008562
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The growing practice of exploiting noninvasive fluorescence-based techniques to study G protein-coupled receptor pharmacology at the single cell and single molecule level demands the availability of high-quality fluorescent ligands. To this end, this study evaluated a new series of red-emitting ligands for the human beta-adrenoceptor family. Upon the basis of the orthosteric ligands propranolol, alprenolol, and pindolol, the synthesized linker-modified congeners were coupled to the commercially available fluorophore BODIPY 630/650-X. This yielded high-affinity beta-adrenoceptor fluorescent ligands for both the propranolol and alprenolol derivatives; however, the pindolol-based products displayed lower affinity. A fluorescent diethylene glycol linked propranolol derivative (18a) had the highest affinity (log K-D of -9.53 and -8.46 as an antagonist of functional beta 2- and beta 1-mediated responses, respectively). Imaging studies with this compound further confirmed that it can be employed to selectively label the human beta 2-adrenoceptor in single living cells, with receptor-associated binding prevented by preincubation with the nonfluorescent beta 2-selective antagonist 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]-butan-2-ol (ICI 118551) (J. Cardiovasc. Pharmacol. 1983, 5,430-437.)
引用
收藏
页码:6874 / 6887
页数:14
相关论文
共 55 条
[1]   Do low-affinity states of β-adrenoceptors have roles in physiology and medicine? [J].
Arch, JRS .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) :517-518
[2]   DIRECT MAPPING OF BETA-ADRENERGIC RECEPTORS IN RAT CENTRAL NERVOUS-SYSTEM BY A NOVEL FLUORESCENT BETA-BLOCKER [J].
ATLAS, D ;
MELAMED, E .
BRAIN RESEARCH, 1978, 150 (02) :377-385
[3]   The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors [J].
Baker, JG .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (03) :317-322
[4]   Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signaling [J].
Baker, JG ;
Hall, IP ;
Hill, SJ .
MOLECULAR PHARMACOLOGY, 2003, 64 (06) :1357-1369
[5]   Pharmacology and direct visualisation of BODIPY-TMR-CGP:: a long-acting fluorescent β2-adrenoceptor agonist [J].
Baker, JG ;
Hall, IP ;
Hill, SJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (02) :232-242
[6]   Agonist actions of "β-blockers" provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor [J].
Baker, JG ;
Hall, IP ;
Hill, SJ .
MOLECULAR PHARMACOLOGY, 2003, 63 (06) :1312-1321
[7]   Site of action of β-ligands at the human β1-adrenoceptor [J].
Baker, JG .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) :1163-1171
[8]   Evidence for a secondary state of the human β3-adrenoceptor [J].
Baker, JG .
MOLECULAR PHARMACOLOGY, 2005, 68 (06) :1645-1655
[9]   Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates [J].
Baker, Jillian G. ;
Hill, Stephen J. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (08) :374-381
[10]   Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling [J].
Baker, Jillian G. ;
Hill, Stephen J. ;
Summers, Roger J. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (04) :227-234